What is iHear Medical?
iHear Medical operates at the intersection of consumer electronics and medical-grade audiology. The company specializes in the development and distribution of advanced hearing devices designed to bypass traditional, high-cost clinical channels. By focusing on accessible, over-the-counter health solutions, iHear Medical addresses the significant market gap for affordable hearing assistance. Their business model is built upon the premise that high-quality health outcomes should not be restricted by prescription requirements or prohibitive pricing, thereby empowering seniors and the hearing-impaired through a streamlined, user-centric digital platform.
How much funding has iHear Medical raised?
iHear Medical has raised a total of $9.6M across 5 funding rounds:
Series A
$475K
Series B
$1.8M
Series C
$5M
Debt
$2.3M
Debt
$70K
Series A (2010): $475K with participation from Aphelion Capital
Series B (2012): $1.8M, investors not publicly disclosed
Series C (2014): $5M supported by Ameritas Holding Company, Aphelion Capital, and Lighthouse Capital
Debt (2017): $2.3M featuring Ameritas Life Insurance Corp and Aphelion Capital
Debt (2021): $70K backed by PPP
Key Investors in iHear Medical
Aphelion Capital
Aphelion Capital invests in medical technology companies across all stages and therapeutic areas, but strongly prefers investments in companies that improve quality of care while reducing costs in the company's healthcare system.
Ameritas Holding Company
Ameritas, headquartered in Lincoln, Nebraska, is a mutual insurance company offering life, dental, and disability insurance, as well as financial services.
Lighthouse Capital
Lighthouse Capital provides strategic financial backing to companies that demonstrate a clear understanding of client needs and a commitment to high-quality, scalable results.
What's next for iHear Medical?
With the recent infusion of capital, iHear Medical is poised to scale its operational footprint and enhance its product development pipeline. The strategic focus will likely shift toward expanding market penetration and refining its supply chain to support broader distribution. As the company transitions into this next phase of maturity, the emphasis will remain on maintaining clinical efficacy while optimizing the user experience. Investors are closely monitoring how this capital will be deployed to capture a larger share of the growing wellness and hearing-aid market, particularly as regulatory environments continue to favor accessible, non-prescription health technologies.
See full iHear Medical company page
